NanoVibronix Shares Positive Results from UroShield Case Series

NanoVibronix Inc. is disclosing encouraging findings from a recent retrospective case series evaluating the UroShield system’s clinical impact and patient experiences.

Conducted between September 2023 and January 2025 by researchers at University Hospitals Coventry and Warwickshire Partnership NHS, the case series assessed a small patient group that used the UroShield device for durations ranging from 12 weeks to 17 months. The series reviewed pre- and post-treatment data on catheter-associated urinary tract infections (CAUTIs), catheter blockages, unplanned hospital visits and patient satisfaction.

Key outcomes included:

• A 94% average reduction in CAUTIs and catheter blockages;
• A 92% decrease in unplanned hospital visits;
• Extended intervals between catheter changes, improving patient comfort and quality of life;
• High patient compliance and satisfaction; and
• Only one case of discontinued use due to worsening of pre-existing bladder symptoms.

These outcomes reinforce previous study results, including those by Markowitz et al. (2018)¹ and Da Silva, Ibbotson, and O’Neil (2021),² that indicated UroShield’s effectiveness in reducing infection risk, improving catheter management, and enhancing overall patient outcomes.

“We believe this case series reinforces the growing body of clinical evidence supporting UroShield as an effective solution for minimizing catheter-associated risks, improving patient care and the quality of life for patients living with long-term catheterization while reducing healthcare burden,” NanoVibronix CEO Brian Murphy said. “The results of this series are another strong affirmation of the device’s value for both patient care and healthcare cost reduction.”

UroShield uses proprietary Surface Acoustic Wave (SAW) technology to prevent bacterial colonization and biofilm formation on indwelling urinary catheters, a critical advancement in reducing complications such as CAUTIs.

Headquartered in Tyler, Texas, with research and development in Nesher, Israel, NanoVibronix develops medical devices that use its patented low intensity surface acoustic wave (SAW) technology. This proprietary technology creates low-frequency ultrasound waves that can be used in various medical applications, including for disrupting biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the continuous assistance of medical professionals. The company’s primary products include PainShield and UroShield, which are portable devices suitable for administration at home or in any care setting.

References
¹ Markowitz. S., Rosenblum. J., Goldstein. M., Gadagkar. H.P., and Litman. L. (2018) The effect of surface acoustic waves on bacterial load and preventing catheter-associated urinary tract infections (CAUTI) in long term indwelling catheters
² Da Silva. K., Ibbotson. A., and O’Neil. M. (2021) The effectiveness of UroShield in reducing urinary tract infections and patients’ pain complaints: Retrospective Data Analysis from Clinical Practice.